Corporate News Blog – Regeneron and Sanofi Announced Kevzara Approval by the European Commission

LONDON, UK / ACCESSWIRE / June 29, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=REGN. Regeneron Pharma and Sanofi (NYSE: SNY) announced on June 27, 2017, that the European Commission has granted marketing authorization for Kevzara (sarilumab) in combination with methotrexate (MTX) for the treatment of moderately to severely active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti-rheumatic drugs (DMARDs), like MTX. Kevzara, according to Regeneron, can be used as monotherapy in case of intolerance to MTX, or when treatment with methotrexate is inappropriate. For immediate access to our complimentary reports, including today’s coverage, register for free now at:

http://protraderdaily.com/register/

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on REGN and SNY. Go directly to your stock of interest and access today’s free coverage at:

http://protraderdaily.com/optin/?symbol=REGN

Rheumatoid Arthritis

RA is a difficult-to-treat, lifelong disease, where many healthcare providers are challenged with finding a treatment that works for their patients. RA affects about 2.9 million people in Europe itself, where in the immune system it attacks the tissues of the joints, causing inflammation, joint pain, swelling, stiffness, fatigue and eventually joint damage and disability, and is most common in those aged between 35 to 50 years old.

Kevzara is indicated for the treatment of adult patients with moderately to severely active RA, who have had an inadequate response to one or more DMARDs. Kevzara is a human monoclonal antibody that binds to the interleukin-6 receptor (IL-6R) and blocks pro-inflammatory IL-6 mediated signaling. Patients with RA usually have elevated levels of IL-6 in their synovial fluid, where both pathologic inflammation and joint destruction are hallmarks of RA. Kevzara was developed using the Company’s proprietary VelocImmune technology that yields optimized full-human antibodies.

The EC Approval

The EC Approval based on a positive opinion by European Medicine Agency (EMA) Committee for Medicinal Products for Human Use (CHMP), evaluated results from seven Phase-3 trials, in the global SARIL-RA clinical development program. The studies incorporate data from about 3,300 adults with moderately to severely active RA, who have had an inadequate response or intolerance to one or more biologic or non-biologic DMARDs.

In the Phase-3 MONARCH study, Kevzara 200 mg was indicated against adalimumab 40mg (also known as HUMIRA by AbbVie) monotherapy, where the former was observed in reducing disease activity and improving physical function, with more patients achieving clinical remission over 24 weeks. In Phase-study with Kevzara plus MTX, reduced signs and symptoms of RA were observed, with improved physical function. At week 52, it inhibited the progression of structural damage by 91% for the Kevzara 200 mg dose and 68% for Kevzara 150 mg dose, compared to placebo plus MTX.

The Delayed FDA Approval

Last year, in October 2016, Sanofi and Regeneron expected that at the end of the month, i.e., the PDUFA date, the Companies would get the US nod for its IL-6R contender in RA. However, the Companies were hit by a complete response letter from the FDA for manufacturing concerns, where experimental med sarilumab faced months of delay. According to the Companies, FDA disapproved the med over certain deficiencies identified during a routine good manufacturing practice inspection of the Sanofi Le Trait Facility. However, on May 22, 2017, after almost 7 months of delay, the Companies received FDA approval for sarilumab, paving the path for future development and eligibility for manufacturing and sales of sarilumab in the US.

Last Close Stock Review

At the closing bell, on Wednesday, June 28, 2017, Regeneron Pharma’s stock climbed 2.20%, ending the trading session at $513.19. A total volume of 932.79 thousand shares have exchanged hands. The Company’s stock price skyrocketed 30.20% in the last three months, 32.97% in the past six months, and 51.04% in the previous twelve months. Moreover, the stock soared 39.80% since the start of the year. The stock is trading at a PE ratio of 61.74 and currently has a market cap of $54.08 billion.

Sanofi’s share price finished yesterday’s trading session flat at $49.29. A total volume of 830.26 thousand shares have exchanged hands. The Company’s stock price surged 8.88% in the last three months, 24.19% in the past six months, and 21.55% in the previous twelve months. Additionally, the stock rallied 21.88% since the start of the year. Shares of the Company have a PE ratio of 24.29 and have a dividend yield of 3.33%. The stock currently has a market cap of $120.69 billion.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily

ReleaseID: 467093